Clinical Trial Update: CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating HSP-CAR30 CAR T-cells targeting CD30 for relapsed/refractory Hodgkin lymphoma and T-cell lymphoma is ongoing, with status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• T-cell Lymphoma

Drugs mentioned

• HSP-CAR30 (CAR T-cell therapy targeting CD30)

Snippet

Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Conditions: Hodgkin Lymphoma, Adult, T Cell Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN